Shalom Auerbach Sells 16,720 Shares of OS Therapies Inc (NYSE:OSTX) Stock

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 16,720 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total value of $112,692.80. Following the sale, the insider now owns 2,531,211 shares of the company’s stock, valued at approximately $17,060,362.14. This trade represents a 0.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

OS Therapies Stock Performance

Shares of NYSE:OSTX traded down $1.17 during midday trading on Friday, reaching $2.95. 1,628,859 shares of the company’s stock were exchanged, compared to its average volume of 1,970,632. The business has a 50 day moving average price of $3.32. OS Therapies Inc has a 12 month low of $1.58 and a 12 month high of $7.00.

Institutional Investors Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC acquired a new position in shares of OS Therapies Inc (NYSE:OSTX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

Analyst Ratings Changes

Several research analysts recently commented on OSTX shares. D. Boral Capital reiterated a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a report on Wednesday. Maxim Group lifted their price objective on OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.